MD Anderson received FDA IND clearance to start a phase I trial of JV-394, a CD94-targeted CAR T therapy for patients with relapsed or refractory CD94-positive T/natural killer cell lymphomas. The clearance sets the stage for first-in-human evaluation of safety, dose-escalation and preliminary efficacy in a difficult-to-treat subgroup. The trial represents a targeted immunotherapy approach where antigen selection aims to improve specificity relative to broader CAR T targets. CD94 is part of the NKG2/CD94 complex in immune biology, and selection is intended to enable CAR recognition on relevant malignant cells. For biotech and translational teams, IND-enabling clearance is a concrete regulatory step that can attract further partnerships and support manufacturing readiness, especially if institutional results guide later multicenter studies. Patients and clinicians will likely focus on early toxicity signals and on persistence and trafficking markers that predict durability of CAR T responses in CD94-positive disease.